Skip Navigation


Rheumatology Advance Access originally published online on October 19, 2004
Rheumatology 2005 44(2):176-182; doi:10.1093/rheumatology/keh443
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/2/176    most recent
keh443v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tokunaga, M.
Right arrow Articles by Tanaka, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tokunaga, M.
Right arrow Articles by Tanaka, Y.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 2 © British Society for Rheumatology 2004; all rights reserved

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

M. Tokunaga, K. Fujii, K. Saito, S. Nakayamada, S. Tsujimura, M. Nawata and Y. Tanaka

First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Kitakyushu 807-8555, Japan.

Correspondence to: Y. Tanaka, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Kitakyushu 807-8555, Japan. E-mail: tanaka{at}med.uoeh-u.ac.jp

Objectives. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoreactive T cells and polyclonally activated B cells that produce autoantibodies. Five SLE patients who failed to respond to conventional immunosuppressants were treated with anti-CD20 antibody (rituximab) and their clinical manifestations and laboratory data were evaluated, including phenotypic analysis of B cells.

Methods. Rituximab (375 mg/m2) was administered weekly for 2 weeks in five SLE patients who developed severe manifestations despite intensive treatment.

Results. Rituximab resulted in rapid improvement (within several days) in clinical manifestations such as consciousness disorder, seizures, progressive sensory disorder, haemolytic crisis, cardiac function and laboratory data. The effects lasted 20 months in one patient; other patients were in remission for more than 6 months. Flow cytometric analysis revealed down-regulation of CD40 and CD80 expression on CD19-positive B cells 1 week after infusion of rituximab, and such down-regulation was seen for more than 7 months in two patients.

Conclusions. Our pilot study provides sufficient evidence of excellent tolerability and high efficacy of rituximab therapy in refractory SLE. Rituximab not only reduced B-cell number and IgG levels but down-regulated CD40 and CD80 on B cells, suggesting possible disturbance of T-cell activation through these costimulatory molecules. Reduction of both quantity and quality of B cells suggests that rituximab could improve the disease course in patients with refractory SLE.

KEY WORDS: Rituximab, Anti-CD20 antibody, Systemic lupus erythematosus, Central nervous system lupus, Autoimmune haemolytic anaemia, CD40, CD80


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
Y. Tamimoto, T. Horiuchi, H. Tsukamoto, J. Otsuka, H. Mitoma, Y. Kimoto, H. Nakashima, K. Muta, Y. Abe, C. Kiyohara, et al.
A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines
Rheumatology, June 1, 2008; 47(6): 821 - 827.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al.
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Ann Rheum Dis, April 1, 2007; 66(4): 470 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.
Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. Okamoto
Effect of rituximab in refractory SLE: inhibition of Th1?
Rheumatology, January 1, 2006; 45(1): 121 - 122.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
Y. Tanaka and M. Tokunaga
Rituximab reduces both quantity and quality of B cells in SLE: reply
Rheumatology, January 1, 2006; 45(1): 122 - 123.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. Saito, M. Nawata, S. Iwata, M. Tokunaga, and Y. Tanaka
Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus
Rheumatology, November 1, 2005; 44(11): 1462 - 1464.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.